Assessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile Dysfunction

Summary

To determine the onset of action, safety and toleration of different formulations and doses of UK-369,003 in patients with erectile dysfunction. Patients should have been previously treated with PDE5 inhibitors and have been responders to the drugs. Duration of treatment is 4 weeks.

Timeline

Start

2005-02

Primary completion

—

Completion

2005-08

Drugs

Indications